- Home
- / Elicio Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Elicio Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$4.3
2024-10-29
Market Capitalization
$47.5 M
2024-10-28
Revenue
$2.3 M
FY, 2022
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 28.3M | 2.3M | |||
| Cost of goods sold | 433.0K | ||||
| Gross profit | 27.9M | ||||
| Gross profit margin, % | 98.5% | ||||
| General and administrative expense | 18.5M | 14.6M | 11.9M | 11.3M | 12.8M |
| Operating expense total | 67.2M | 41.9M | 35.7M | 45.0M | 37.7M |
| EBIT | (39.3M) | (39.6M) | (35.7M) | (45.0M) | (37.7M) |
| EBIT margin, % | -138.8% | -1721.9% | |||
| Investment income | (96.0K) | 151.0K | |||
| Interest expense | 1.8M | 805.0K | 1.1M | ||
| Pre tax profit | (54.6M) | (38.8M) | (39.6M) | ||
| Income tax expense | 11.0K | ||||
| Net Income | (54.6M) | (38.8M) | (35.2M) | (51.9M) | (39.6M) |
| EPS | (1.9) | (1.3) | (7.0) | (4.2) | (2.6) |